NKTX

Nkarta Inc

NKTX, USA

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

https://www.nkartatx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NKTX
stock
NKTX

This trade activity should not be overlooked: Nkarta Inc (NKTX) setenews.com

Read more →
NKTX
stock
NKTX

Nkarta (NASDAQ:NKTX) Downgraded by Wall Street Zen to Sell Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$11.25

Analyst Picks

Strong Buy

4

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.41

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-6.43 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-5.08 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.26

Low 1

High 0.3

Investors

* Institutions hold a combined 85.03% of the total shares of Nkarta Inc

1.

RA Capital Management, LLC

(15.2132%)

since

2025/06/30

2.

TANG CAPITAL MANAGEMENT LLC

(9.934%)

since

2025/06/30

3.

BlackRock Inc

(5.8485%)

since

2025/06/30

4.

Samsara BioCapital, LLC

(5.3053%)

since

2025/06/30

5.

NEA Management Company, LLC

(5.0247%)

since

2025/06/30

6.

SR ONE CAPITAL MANAGEMENT, LP

(4.6932%)

since

2025/06/30

7.

Citadel Advisors Llc

(4.6432%)

since

2025/06/30

8.

Vanguard Group Inc

(3.5963%)

since

2025/06/30

9.

Alyeska Investment Group, L.P.

(2.9352%)

since

2025/06/30

10.

Wasatch Advisors LP

(2.5149%)

since

2025/06/30

11.

Wasatch Ultra Growth

(2.2317%)

since

2025/06/30

12.

Monaco Asset Management

(2.2293%)

since

2025/06/30

13.

Vanguard Total Stock Mkt Idx Inv

(1.9996%)

since

2025/07/31

14.

iShares Russell 2000 ETF

(1.7523%)

since

2025/08/31

15.

Geode Capital Management, LLC

(1.7014%)

since

2025/06/30

16.

State Street Corp

(1.6022%)

since

2025/06/30

17.

Biotech Growth Ord

(1.1565%)

since

2025/05/31

18.

Affinity Asset Advisors, LLC

(1.1264%)

since

2025/06/30

19.

Blackstone Inc

(1.0518%)

since

2025/06/30

20.

Bank of America Corp

(1.0457%)

since

2025/06/30

21.

Awm Investment Company Inc

(0.9856%)

since

2025/06/30

22.

Renaissance Technologies Corp

(0.9805%)

since

2025/06/30

23.

Peapod Lane Capital LLC

(0.9347%)

since

2025/06/30

24.

Goldman Sachs Group Inc

(0.836%)

since

2025/06/30

25.

JPM Thematics Genetic Thrps C2 dist USD

(0.7637%)

since

2025/07/31

26.

Fidelity Small Cap Index

(0.7511%)

since

2025/06/30

27.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6818%)

since

2025/07/31

28.

iShares Russell 2000 Value ETF

(0.6649%)

since

2025/08/31

29.

iShares Biotechnology ETF

(0.4338%)

since

2025/08/31

30.

Vanguard Russell 2000 ETF

(0.3631%)

since

2025/07/31

31.

Fidelity Extended Market Index

(0.3615%)

since

2025/07/31

32.

State St Russell Sm Cap® Indx SL Cl I

(0.3106%)

since

2025/08/31

33.

A4Investments SICAV SIF ACCI IlanaA2EURH

(0.2253%)

since

2025/08/31

34.

Schwab Small Cap Index

(0.1961%)

since

2025/07/31

35.

NT R2000 Index Fund - NL

(0.1881%)

since

2025/06/30

36.

iShares Micro-Cap ETF

(0.1677%)

since

2025/08/31

37.

NT R2000 Index Fund - DC - NL - 3

(0.15%)

since

2025/06/30

38.

Vifag 2002 SICAV

(0.1478%)

since

2025/07/31

39.

Extended Equity Market Fund K

(0.1401%)

since

2025/06/30

40.

SPDR® Russell 2000 US Small Cap ETF

(0.1396%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.29

EPS Estimate

-0.338

EPS Difference

0.048

Surprise Percent

14.2012%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Possible Net-Net(6)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.